Boston Scientific (NYSE:BSX) posts better-than-expected sales in Q3 2026 but quarterly revenue guidance misses expectations
Boston Scientific reported Q3 2026 revenue of $5.14 billion, exceeding estimates by 1.4%, but missed revenue and EPS guidance for Q4 2026. Adjusted EPS was in line at $0.73. Operating margin declined to 16.1% from 20.7% year-over-year, and organic revenue grew 1.5%.
How this was made
The 30-second read
Why it matters
Traders will likely focus on the forward guidance gap: Q4 revenue midpoint of $5.18B versus $5.42B consensus, and a full-year adjusted EPS midpoint cut to $3.17.
Market read
A clear earnings-guidance setup with a Q3 beat but weaker forward revenue and lowered full-year EPS guidance, plus margin compression.
What to watch
Operating margin fell to 16.1% from 20.7% a year ago, which may reflect mix or cost pressures that could persist into subsequent quarters if not addressed.
Background
The article summarizes Boston Scientific’s Q3 2026 results versus analyst consensus and highlights guidance changes for Q4 2026 revenue and full-year adjusted EPS.
Ticker impact
Boston Scientific reported Q3 2026 revenue of $5.14B vs $5.07B consensus, but guided Q4 revenue to $5.18B below $5.42B expectations.
Likely near-term pressure as the market reprices the forward revenue and EPS outlook despite the Q3 beat.
The article’s decision-relevant new facts are the Q4 revenue midpoint guidance miss and the full-year adjusted EPS guidance cut, both directly tied to BSX’s forward earnings power.
Market effects
Medical device peers may see read-across on demand durability and pricing, given BSX’s organic growth beat paired with weaker forward guidance.
Limited, as this is company-specific guidance rather than a broad macro release.
Low, since the disclosed catalysts are tied to BSX’s own quarterly and full-year outlook.
Counterpoint
The Q3 revenue and organic growth beats plus in-line adjusted EPS could indicate the guidance miss is temporary, driven by timing rather than underlying demand weakness.
Key entities
- companyBoston Scientific
US-listed medical device company reporting Q3 2026 results and issuing Q4 revenue and full-year adjusted EPS guidance.
